SOM0226 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 28 | Systemic amyloidosis | 2 |
28. Systemic amyloidosis
Clinical trials : 267 / Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-001586-27-ES (EUCTR) | 25/07/2014 | 02/06/2014 | Study of SOM0226 in familial amyloid polyneuropathy (FAP) patients and asymptomatic carriers to evaluate protein stabilization activity | Study of SOM0226 in familial amyloid polyneuropathy (FAP) patients and asymptomatic carriers to evaluate protein stabilization activity | Patients with familial amyloid polyneuropathy (FAP), asymptomatic carriers and healthy volunteers MedDRA version: 17.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tasmar INN or Proposed INN: TOLCAPONE | SOM Innovation Biotech SL (SOM Biotech) | NULL | Not Recruiting | Female: yes Male: yes | Spain | ||||
| 2 | NCT02191826 (ClinicalTrials.gov) | July 2014 | 9/7/2014 | Study of SOM0226 in Familial Amyloid Polyneuropathy | Study of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization Activity | Familial Amyloid Polyneuropathy (FAP) | Drug: SOM0226 | SOM Biotech SL | Hospital Vall d'Hebron | Completed | 18 Years | N/A | Both | 17 | Phase 1/Phase 2 | Spain |